Core Viewpoint - The company reported its sales revenue from high-flow and low-flow dialysis devices and blood dialysis tubing through centralized procurement for the years 2024 and the first half of 2025, indicating a gradual increase in revenue contribution from these products [1] Group 1: Sales Revenue from Centralized Procurement - In 2024, the sales revenue from high-flow and low-flow dialysis devices through centralized procurement was 9.62 million yuan, accounting for 0.36% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in 2024 was 3.36 million yuan, representing 0.13% of the total revenue [1] - For the first half of 2025, the sales revenue from high-flow and low-flow dialysis devices through centralized procurement reached 15.2 million yuan, making up 1.34% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in the first half of 2025 was 2.45 million yuan, which accounted for 0.22% of the total revenue [1] Group 2: Product Inclusion in Centralized Procurement - As of now, the company's main product, blood perfusion devices, has not been included in the centralized procurement scope at the national or provincial levels [1]

Core Viewpoint - The company Jianfan Bio reported a significant reduction in sales expenses for the first half of 2025, indicating improved cost management and operational efficiency [1] Summary by Categories Financial Performance - Sales expenses for the first half of 2025 are projected to be 24.961 million yuan, representing a year-on-year decrease of 26.75% [1]

Core Viewpoint - The company, Jianfan Biological, reported that its overseas market revenue reached 34.44 million yuan in the first half of 2025, accounting for 3.04% of the total company revenue [1] Group 1 - The overseas market revenue for Jianfan Biological in the first half of 2025 was 34.44 million yuan [1] - This overseas revenue represents 3.04% of the company's total revenue [1]

Group 1 - The company has reported overseas revenue of 34.44 million yuan in the first half of 2025, which accounts for 3.04% of its total revenue [2]

Core Viewpoint - The company, Jianfan Biological (300529.SZ), provided insights on its sales performance related to centralized procurement and its overseas market expansion efforts. Group 1: Centralized Procurement Impact - In 2024, the sales revenue from high-flow and low-flow blood dialysis machines through centralized procurement is projected to be 9.62 million yuan, accounting for 0.36% of the total revenue during the same period [1] - The sales revenue from blood dialysis tubing through centralized procurement is expected to be 3.36 million yuan, representing 0.13% of the total revenue [1] - For the first half of 2025, the sales revenue from high-flow and low-flow blood dialysis machines through centralized procurement is anticipated to reach 15.2 million yuan, which will be 1.34% of the total revenue [1] - The sales revenue from blood dialysis tubing through centralized procurement in the same period is projected to be 2.45 million yuan, accounting for 0.22% of the total revenue [1] - Currently, the company's main product, blood perfusion devices, has not been included in the centralized procurement scope at the national or provincial levels [1] Group 2: Overseas Market Development - In the first half of 2025, the company expects to achieve revenue of 34.44 million yuan from overseas markets, which will constitute 3.04% of the total revenue [1] - The company plans to focus on international market expansion by actively engaging in cross-border research collaborations, refining its overseas distributor network, recruiting overseas marketing personnel, and concentrating on key countries [1] - The strategy aims to tap into overseas market opportunities and drive growth in international business through a dual approach of "chronic diseases + acute critical illnesses" [1]

Core Viewpoint - The company has reported a significant reduction in sales expenses and is adjusting the pricing of its blood perfusion device in response to new healthcare policies in China [1] Group 1: Sales Expenses - In the first half of 2025, the company's sales expenses amounted to 24.961 million yuan, representing a year-on-year decrease of 26.75% [1] Group 2: Policy Impact - The National Healthcare Security Administration issued a guideline in June this year, adding "blood dialysis perfusion fee" and "plasma adsorption fee" as new items, which have been officially included in the medical insurance projects with independent pricing standards [1] - Over twenty provinces in China are actively implementing these policies, which are expected to drive growth in the clinical use of blood perfusion and adsorption products [1] Group 3: Pricing Adjustment - Starting from September 2025, the company will adjust the price of its KHA130 blood perfusion device, which is specifically used for maintenance hemodialysis patients, as part of its commitment to social responsibility and patient care [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-074 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 3、转股价格：38.65 元/股 4、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 5、根据公司《健帆生物科技集团股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）规定：在可转债存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格 低于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交 公司股东大会表决。 自 2025 年 9 月 15 日至 2025 年 9 月 26 日，公司股票已有十个交易日低于当 期转股价格的 85%。若触发转股价格修正条件，公司将按照《募集说明书》的约 定及时履行后续审议程序和信 ...

Group 1 - The core point of the article is that Jianfan Bio has announced the transfer of convertible bonds by its controlling shareholder, Dong Fan, which will take place by September 22, 2025 [2][3] - Dong Fan will transfer a total of 1,264,320 "Jianfan Convertible Bonds," representing 12.64% of the total issued convertible bonds [2]

Core Viewpoint - The company, Jianfan Bio, has announced that its controlling shareholder and actual controller, Mr. Dong Fan, will transfer 1,264,320 units of "Jianfan Convertible Bonds" by September 22, 2025, which represents 12.64% of the total issued convertible bonds [1] Group 1 - The transfer of convertible bonds is part of a planned divestment by the controlling shareholder [1] - The total amount of convertible bonds being transferred is significant, indicating a strategic move by the shareholder [1] - The transaction will take place through the Shenzhen Stock Exchange trading system [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-073 债券代码：123117 债券简称：健帆转债 二、债券持有人历次可转债持有比例变动情况 截至 2025 年 9 月 16 日，公司控股股东、实际控制人董凡先生通过深圳证券 交易所交易系统转让其所持有的"健帆转债"1,319,814 张，占本次发行可转换 公司债券总量的 13.20%。转让后董凡先生持有"健帆转债"3,037,830 张，占本 次发行可转换公司债券总量的 30.38%。具体内容详见公司 2025 年 9 月 17 日刊 载于巨潮资讯网（www.cninfo.com.cn）的《关于债券持有人可转债持有比例变 动达到 10%的公告》（公告编号：2025-072）。 公司于近日收到控股股东、实际控制人董凡先生的通知，截至 2025 年 9 月 22 日，董凡先生通过深圳证券交易所交易系统转让其所持有的"健帆转债" 1,264,320 张，占本次发行可转换公司债券总量的 12.64%，具体变动情况如下： 1 健帆生物科技集团股份有限公司 关于债券持有人可转债持有比例变动达到 10%的公告 本公司及董事会全体成员保证信息披露的内容真实、 ...